iA Global Asset Management Inc. Has $823,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

iA Global Asset Management Inc. decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 84.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,157 shares of the life sciences company’s stock after selling 32,865 shares during the period. iA Global Asset Management Inc.’s holdings in Illumina were worth $823,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Versant Capital Management Inc increased its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $32,000. Assetmark Inc. increased its holdings in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $45,000. Finally, TD Private Client Wealth LLC increased its holdings in shares of Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research reports. Robert W. Baird lowered their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Canaccord Genuity Group lowered their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, March 11th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Finally, HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Trading Up 3.4 %

ILMN opened at $87.66 on Friday. The stock has a market capitalization of $13.89 billion, a P/E ratio of -11.41, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 12 month low of $80.18 and a 12 month high of $156.66. The firm’s fifty day simple moving average is $108.20 and its 200 day simple moving average is $128.27. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.